Swiss National Bank Decreases Stake in Moderna, Inc. (NASDAQ:MRNA)

Swiss National Bank lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 923,000 shares of the company’s stock after selling 43,800 shares during the quarter. Swiss National Bank owned about 0.24% of Moderna worth $38,378,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB grew its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc purchased a new stake in shares of Moderna during the 4th quarter worth about $37,000. Larson Financial Group LLC grew its holdings in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA opened at $34.62 on Monday. The business’s fifty day moving average price is $35.94 and its 200 day moving average price is $47.15. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The stock has a market capitalization of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Citigroup assumed coverage on shares of Moderna in a research report on Thursday. They issued a “neutral” rating and a $40.00 price objective for the company. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.